Cisplatin resistance in ovarian cancer was associated with increased expression and activity of glucose-6-phosphate dehydrogenase (G6PD), which enabled greater NADPH production via the PPP for redox homeostasis [55]. Here, G6PD is linked to ovarian carcinoma.